Inflammatory Bowel Diseases (IBD)
8
3
4
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (8)
BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD)
Study of Tissue Repair in Inflammatory Bowel Disease Exploiting Organoid Technology
Evaluating the Effectiveness of 68Ga-grazytracer PET/CT in Inflammatory Bowel Disease
Development and Validation of a New Paediatric Inflammatory Bowel Disease NUTrition Risk Score (PIBD-NUTS)
The Colonic Microbiome and Mucosal Immunity in Inflammatory Bowel Disease and Ankylosing Spondylitis
NORDTREAT Prospective Study on Inflammatory Bowel Disease
Osteopathic Approach in Inflammatory Bowel Diseases
Fecal Microbiota Transplantation in Pediatric Patients